METTL3 and urinary bladder carcinoma: In bladder cancer, METTL3 upregulates PCAT6 expression and increases IGF1R RNA stability by forming the PCAT6/IGF2BP2/IGF1R complex [91], which activates the NF-KB and PI3K/AKT signaling pathways.